Comparing the current results to its competitors, Bioxcel Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 51.67 % year on year. The sales growth was above Bioxcel Therapeutics Inc 's competitors' average revenue growth of 16.74 %, achieved in the same quarter.
Due to outstanding performance in Overall company, revenue grew by 51.67 % Bioxcel Therapeutics Inc improved its market share, to approximately 0.01 %.
July 16, 2024
BioXcel Therapeutics, a leading innovator in the pharmaceutical industry, recently released an announcement regarding the preliminary estimated unaudited second-quarter net revenues generated from sales of their highly anticipated product IGALMI (dexmedetomidine) Sublingual Film. With a focused market-access strategy, the company achieved an estimated net revenue of approximately $1.1 million, marking its highest quarterly net revenue since the commercial launch of the product.Outline of Facts:1. Record-Breaking Net Revenue: BioXcel Therapeutics reported an estimated net revenue of approximately $1.1 million for the second quarter of the year, following the sales performance of their groundbreaking product I...
April 22, 2024
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialBioXcel Therapeutics, a clinical-stage biopharmaceutical company focused on drug development utilizing artificial intelligence (AI) solutions, has recently announced its plans to initiate the SERENITY At-Home pivotal Phase 3 safety trial with a 120 mcg dose of BXCL501. This exciting move comes after a constructive meeting between BioXcel Therapeutics and the U.S. Food and Drug Administration (FDA). The initiation of this trial aims to expand the market potential of BXCL501, an investigational, proprietary sublingual thin film formulation of dexmedetomidine.BXCL501 has demonstrated promising results...
February 6, 2024
BioXcel Therapeutics, a clinical-stage biopharmaceutical company, has achieved an important milestone in its investigator-sponsored Phase 2 relapsed pancreatic cancer trial. The firm announced the completion of patient enrollment in a critical safety portion of the study, proposing a potential new treatment option for an aggressive form of cancer. The therapy trial involves BioXcel s BXCL701 in combination with Merck s KEYTRUDA.Phase 2 of this trial was designed to assess the safety and tolerability of the BXCL701 and KEYTRUDA combination. The patients enrolled for the trial are those who have not responded to standard of care treatments. Pancreatic cancer is notoriously resistant to most traditional cancer ...
Inmed Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of cannabinoid-based therapies for various diseases. The company's business model revolves around conducting research and development to identify novel drug candidates, conducting pre-clinical and clinical trials to test the safety and efficacy of these candidates, and seeking partnerships or collaborations with other pharmaceutical companies for the further development and commercialization of successful therapies. By leveraging advancements in cannabinoid science, Inmed Pharmaceuticals aims to provide innovative medical treatments for unmet medical needs.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Bioxcel Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bioxcel Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
